Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

BACKGROUND/AIM: Lysozyme (mucopeptide N-acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. METHODS: In a 1-year, randomized, double-blind, placebo-controlled, parallel trial...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Chron Obstruct Pulmon Dis
Asıl Yazarlar: Fukuchi, Yoshinosuke, Tatsumi, Koichiro, Inoue, Hiromasa, Sakata, Yukinori, Shibata, Kai, Miyagishi, Hideaki, Marukawa, Yasuhiro, Ichinose, Masakazu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2016
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846053/
https://ncbi.nlm.nih.gov/pubmed/27143873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S103105
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller